Nab-Paclitaxel Combo Improves Response vs SOC in HER2+ Breast Cancer
Nab-paclitaxel elicited a pathologic complete response rate of 66.3% compared with 57.6% with docetaxel plus carboplatin, the phase 3 HELEN-006 trial found.
Related Articles
Project documents | Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907] | Guidance | NICE
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]
AACR-Johnson & Johnson Interventional Oncology Stimulating Therapeutic Advances through Research Training (START) Grants
Three-year grant of $225,000 to support the salary and benefits of postdoctoral or clinical research fellows conducting lung cancer research.
ELCIN: elacestrant in CDK4/6 inhibitor-naïve ER+/HER2- metastatic breast cancer
Virginia Kaklamani, MD, UT Health San Antonio, San Antonio, TX, discusses the rationale and design of the Phase II ELCIN trial (NCT05596409) of elacestrant in…
Radiation Myelitis After Hypofractionated Spine Stereotactic Body Radiation Therapy
This cohort study characterizes the risk of radiation myelitis after spine stereotactic body radiation therapy to update the current dosimetric constraints.
Better Together: Spatial Arrangement of Three Immune Cells Is Key to
In order for immune cells to effectively kill cancer cells, a triad of three cells are necessary — a dendritic cell, a cytotoxic “killer” T…
11 new research advances from the past year
Researchers and clinicians at MD Anderson continue to lead the way in making new discoveries and leading groundbreaking studies that advance cancer research and bring…
Registration
Registration details for AACR IO: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy
Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia
Key PointsThe prevalence of myeloid CHIP in patients with CLL was 12% in untreated and 24% in treated patients (85% with prior chemotherapy exposure).The p
Saliva of persons with hemophilia A triggers coagulation via extrinsic tenase complexes
Key PointsExtrinsic tenase complexes are present in saliva of persons with hemophilia A and absent in saliva of persons with FVII deficiency.Presence or ab
Welcome! You are invited to join a webinar: Post-ASH 2024 Myeloma highlights webinar. After registering, you will receive a confirmation email about joining the webinar.
Join us to watch leading Myeloma experts present summaries on the most significant abstracts from ASH 2024 followed by interactive panel discussions debating current clinical…
